Drug intelligence / Profile preview

VXCO-100

Development stage: Phase 1
Lead developer: Vaccine Industrial Company
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VXCO-100 is an intramuscularly administered vaccine candidate developed by Vaccine Company, Inc. for the prevention of COVID-19 infections caused by SARS-CoV-2. It is classified as a COVID-19 vaccine and functions as an immunostimulant, aiming to trigger an immune response against the virus. The vaccine is currently in phase 1 clinical trials in both the United States and South Africa, where its safety and immunogenicity are being evaluated at multiple dose levels in healthy adults[1][2][3][4][5]. As of now, it has not received regulatory approval or orphan drug designation.

Other names: VXCO 100VXCO100VXCO-100

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on VXCO-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXCO-100.

Explore the full profile